Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis

Hemant S. Murthy; Mei Jie Zhang; Karen Chen; Sairah Ahmed; Uday Deotare; Siddhartha Ganguly; Ankit Kansagra; Fotios V. Michelis; Taiga Nishihori; Mrinal M Patnaik; Muhammad Bilal Abid; Mahmoud Aljurf; Yasuyuki Arai; Ulrike Bacher; Talha Badar; Sherif M. Badawy; Karen Ballen; Minoo Battiwalla; Amer Beitinjaneh; Nelli Bejanyan; Vijaya Raj Bhatt; Valerie I. Brown; Rodrigo Martino; Jean Yves Cahn; Paul Castillo; Jan Cerny; Saurabh Chhabra; Edward Copelan; Andrew Daly; Bhagirathbhai Dholaria; Miguel Angel Diaz Perez; César O. Freytes; Michael R. Grunwald; Shahrukh Hashmi; Gerhard C. Hildebrandt; Omer Jamy; Jacinth Joseph; Christopher G. Kanakry; Nandita Khera; Maxwell M. Krem; Yachiyo Kuwatsuka; Hillard M. Lazarus; Lazaros J. Lekakis; Hongtao Liu; Dipenkumar Modi; Pashna N. Munshi; Alberto Mussetti; Neil Palmisiano; Sagar S. Patel; David A. Rizzieri; Sachiko Seo; Mithun Vinod Shah; Akshay Sharma; Melhm Sohl; Scott R. Solomon; Matthew Ulrickson; Celalettin Ustun; Marjolein van der Poel; Leo F. Verdonck; John L. Wagner; Trent Wang; Baldeep Wirk; Amer Zeidan; Mark R Litzow; Partow Kebriaei; Christopher S. Hourigan; Daniel J. Weisdorf; Wael Saber; Mohamed A. Kharfan-Dabaja

doi:10.1182/bloodadvances.2023011308

Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis

Hemant S. Murthy, Mei Jie Zhang, Karen Chen, Sairah Ahmed, Uday Deotare, Siddhartha Ganguly, Ankit Kansagra, Fotios V. Michelis, Taiga Nishihori, Mrinal M Patnaik, Muhammad Bilal Abid, Mahmoud Aljurf, Yasuyuki Arai, Ulrike Bacher, Talha Badar, Sherif M. Badawy, Karen Ballen, Minoo Battiwalla, Amer Beitinjaneh, Nelli BejanyanVijaya Raj Bhatt, Valerie I. Brown, Rodrigo Martino, Jean Yves Cahn, Paul Castillo, Jan Cerny, Saurabh Chhabra, Edward Copelan, Andrew Daly, Bhagirathbhai Dholaria, Miguel Angel Diaz Perez, César O. Freytes, Michael R. Grunwald, Shahrukh Hashmi, Gerhard C. Hildebrandt, Omer Jamy, Jacinth Joseph, Christopher G. Kanakry, Nandita Khera, Maxwell M. Krem, Yachiyo Kuwatsuka, Hillard M. Lazarus, Lazaros J. Lekakis, Hongtao Liu, Dipenkumar Modi, Pashna N. Munshi, Alberto Mussetti, Neil Palmisiano, Sagar S. Patel, David A. Rizzieri, Sachiko Seo, Mithun Vinod Shah, Akshay Sharma, Melhm Sohl, Scott R. Solomon, Matthew Ulrickson, Celalettin Ustun, Marjolein van der Poel, Leo F. Verdonck, John L. Wagner, Trent Wang, Baldeep Wirk, Amer Zeidan, Mark R Litzow, Partow Kebriaei, Christopher S. Hourigan, Daniel J. Weisdorf, Wael Saber, Mohamed A. Kharfan-Dabaja

Research output: Contribution to journal › Article › peer-review

Abstract

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with a poor prognosis and considered incurable with conventional chemotherapy. Small observational studies reported allogeneic hematopoietic cell transplantation (allo-HCT) offers durable remissions in patients with BPDCN. We report an analysis of patients with BPDCN who received an allo-HCT, using data reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). We identified 164 patients with BPDCN from 78 centers who underwent allo-HCT between 2007 and 2018. The 5-year overall survival (OS), disease-free survival (DFS), relapse, and nonrelapse mortality (NRM) rates were 51.2% (95% confidence interval [CI], 42.5-59.8), 44.4% (95% CI, 36.2-52.8), 32.2% (95% CI, 24.7-40.3), and 23.3% (95% CI, 16.9-30.4), respectively. Disease relapse was the most common cause of death. On multivariate analyses, age of ≥60 years was predictive for inferior OS (hazard ratio [HR], 2.16; 95% CI, 1.35-3.46; P = .001), and higher NRM (HR, 2.19; 95% CI, 1.13-4.22; P = .02). Remission status at time of allo-HCT (CR2/primary induction failure/relapse vs CR1) was predictive of inferior OS (HR, 1.87; 95% CI, 1.14-3.06; P = .01) and DFS (HR, 1.75; 95% CI, 1.11-2.76; P = .02). Use of myeloablative conditioning with total body irradiation (MAC-TBI) was predictive of improved DFS and reduced relapse risk. Allo-HCT is effective in providing durable remissions and long-term survival in BPDCN. Younger age and allo-HCT in CR1 predicted for improved survival, whereas MAC-TBI predicted for less relapse and improved DFS. Novel strategies incorporating allo-HCT are needed to further improve outcomes.

Original language	English (US)
Pages (from-to)	7007-7016
Number of pages	10
Journal	Blood Advances
Volume	7
Issue number	22
DOIs	https://doi.org/10.1182/bloodadvances.2023011308
State	Published - 2023

ASJC Scopus subject areas

Hematology

Access to Document

10.1182/bloodadvances.2023011308

Cite this

Murthy, H. S., Zhang, M. J., Chen, K., Ahmed, S., Deotare, U., Ganguly, S., Kansagra, A., Michelis, F. V., Nishihori, T., Patnaik, M. M., Abid, M. B., Aljurf, M., Arai, Y., Bacher, U., Badar, T., Badawy, S. M., Ballen, K., Battiwalla, M., Beitinjaneh, A., ... Kharfan-Dabaja, M. A. (2023). Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis. Blood Advances, 7(22), 7007-7016. https://doi.org/10.1182/bloodadvances.2023011308

Murthy, HS, Zhang, MJ, Chen, K, Ahmed, S, Deotare, U, Ganguly, S, Kansagra, A, Michelis, FV, Nishihori, T, Patnaik, MM, Abid, MB, Aljurf, M, Arai, Y, Bacher, U, Badar, T, Badawy, SM, Ballen, K, Battiwalla, M, Beitinjaneh, A, Bejanyan, N, Bhatt, VR, Brown, VI, Martino, R, Cahn, JY, Castillo, P, Cerny, J, Chhabra, S, Copelan, E, Daly, A, Dholaria, B, Perez, MAD, Freytes, CO, Grunwald, MR, Hashmi, S, Hildebrandt, GC, Jamy, O, Joseph, J, Kanakry, CG, Khera, N, Krem, MM, Kuwatsuka, Y, Lazarus, HM, Lekakis, LJ, Liu, H, Modi, D, Munshi, PN, Mussetti, A, Palmisiano, N, Patel, SS, Rizzieri, DA, Seo, S, Shah, MV, Sharma, A, Sohl, M, Solomon, SR, Ulrickson, M, Ustun, C, van der Poel, M, Verdonck, LF, Wagner, JL, Wang, T, Wirk, B, Zeidan, A, Litzow, MR, Kebriaei, P, Hourigan, CS, Weisdorf, DJ, Saber, W & Kharfan-Dabaja, MA 2023, 'Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis', Blood Advances, vol. 7, no. 22, pp. 7007-7016. https://doi.org/10.1182/bloodadvances.2023011308

@article{9af63428f62c4744b027931783821533,

title = "Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis",

abstract = "Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with a poor prognosis and considered incurable with conventional chemotherapy. Small observational studies reported allogeneic hematopoietic cell transplantation (allo-HCT) offers durable remissions in patients with BPDCN. We report an analysis of patients with BPDCN who received an allo-HCT, using data reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). We identified 164 patients with BPDCN from 78 centers who underwent allo-HCT between 2007 and 2018. The 5-year overall survival (OS), disease-free survival (DFS), relapse, and nonrelapse mortality (NRM) rates were 51.2% (95% confidence interval [CI], 42.5-59.8), 44.4% (95% CI, 36.2-52.8), 32.2% (95% CI, 24.7-40.3), and 23.3% (95% CI, 16.9-30.4), respectively. Disease relapse was the most common cause of death. On multivariate analyses, age of ≥60 years was predictive for inferior OS (hazard ratio [HR], 2.16; 95% CI, 1.35-3.46; P = .001), and higher NRM (HR, 2.19; 95% CI, 1.13-4.22; P = .02). Remission status at time of allo-HCT (CR2/primary induction failure/relapse vs CR1) was predictive of inferior OS (HR, 1.87; 95% CI, 1.14-3.06; P = .01) and DFS (HR, 1.75; 95% CI, 1.11-2.76; P = .02). Use of myeloablative conditioning with total body irradiation (MAC-TBI) was predictive of improved DFS and reduced relapse risk. Allo-HCT is effective in providing durable remissions and long-term survival in BPDCN. Younger age and allo-HCT in CR1 predicted for improved survival, whereas MAC-TBI predicted for less relapse and improved DFS. Novel strategies incorporating allo-HCT are needed to further improve outcomes.",

author = "Murthy, {Hemant S.} and Zhang, {Mei Jie} and Karen Chen and Sairah Ahmed and Uday Deotare and Siddhartha Ganguly and Ankit Kansagra and Michelis, {Fotios V.} and Taiga Nishihori and Patnaik, {Mrinal M} and Abid, {Muhammad Bilal} and Mahmoud Aljurf and Yasuyuki Arai and Ulrike Bacher and Talha Badar and Badawy, {Sherif M.} and Karen Ballen and Minoo Battiwalla and Amer Beitinjaneh and Nelli Bejanyan and Bhatt, {Vijaya Raj} and Brown, {Valerie I.} and Rodrigo Martino and Cahn, {Jean Yves} and Paul Castillo and Jan Cerny and Saurabh Chhabra and Edward Copelan and Andrew Daly and Bhagirathbhai Dholaria and Perez, {Miguel Angel Diaz} and Freytes, {C{\'e}sar O.} and Grunwald, {Michael R.} and Shahrukh Hashmi and Hildebrandt, {Gerhard C.} and Omer Jamy and Jacinth Joseph and Kanakry, {Christopher G.} and Nandita Khera and Krem, {Maxwell M.} and Yachiyo Kuwatsuka and Lazarus, {Hillard M.} and Lekakis, {Lazaros J.} and Hongtao Liu and Dipenkumar Modi and Munshi, {Pashna N.} and Alberto Mussetti and Neil Palmisiano and Patel, {Sagar S.} and Rizzieri, {David A.} and Sachiko Seo and Shah, {Mithun Vinod} and Akshay Sharma and Melhm Sohl and Solomon, {Scott R.} and Matthew Ulrickson and Celalettin Ustun and {van der Poel}, Marjolein and Verdonck, {Leo F.} and Wagner, {John L.} and Trent Wang and Baldeep Wirk and Amer Zeidan and Litzow, {Mark R} and Partow Kebriaei and Hourigan, {Christopher S.} and Weisdorf, {Daniel J.} and Wael Saber and Kharfan-Dabaja, {Mohamed A.}",

year = "2023",

doi = "10.1182/bloodadvances.2023011308",

language = "English (US)",

volume = "7",

pages = "7007--7016",

journal = "Blood Advances",

issn = "2473-9529",

publisher = "American Society of Hematology",

number = "22",

}

TY - JOUR

T1 - Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm

T2 - a CIBMTR analysis

AU - Murthy, Hemant S.

AU - Zhang, Mei Jie

AU - Chen, Karen

AU - Ahmed, Sairah

AU - Deotare, Uday

AU - Ganguly, Siddhartha

AU - Kansagra, Ankit

AU - Michelis, Fotios V.

AU - Nishihori, Taiga

AU - Patnaik, Mrinal M

AU - Abid, Muhammad Bilal

AU - Aljurf, Mahmoud

AU - Arai, Yasuyuki

AU - Bacher, Ulrike

AU - Badar, Talha

AU - Badawy, Sherif M.

AU - Ballen, Karen

AU - Battiwalla, Minoo

AU - Beitinjaneh, Amer

AU - Bejanyan, Nelli

AU - Bhatt, Vijaya Raj

AU - Brown, Valerie I.

AU - Martino, Rodrigo

AU - Cahn, Jean Yves

AU - Castillo, Paul

AU - Cerny, Jan

AU - Chhabra, Saurabh

AU - Copelan, Edward

AU - Daly, Andrew

AU - Dholaria, Bhagirathbhai

AU - Perez, Miguel Angel Diaz

AU - Freytes, César O.

AU - Grunwald, Michael R.

AU - Hashmi, Shahrukh

AU - Hildebrandt, Gerhard C.

AU - Jamy, Omer

AU - Joseph, Jacinth

AU - Kanakry, Christopher G.

AU - Khera, Nandita

AU - Krem, Maxwell M.

AU - Kuwatsuka, Yachiyo

AU - Lazarus, Hillard M.

AU - Lekakis, Lazaros J.

AU - Liu, Hongtao

AU - Modi, Dipenkumar

AU - Munshi, Pashna N.

AU - Mussetti, Alberto

AU - Palmisiano, Neil

AU - Patel, Sagar S.

AU - Rizzieri, David A.

AU - Seo, Sachiko

AU - Shah, Mithun Vinod

AU - Sharma, Akshay

AU - Sohl, Melhm

AU - Solomon, Scott R.

AU - Ulrickson, Matthew

AU - Ustun, Celalettin

AU - van der Poel, Marjolein

AU - Verdonck, Leo F.

AU - Wagner, John L.

AU - Wang, Trent

AU - Wirk, Baldeep

AU - Zeidan, Amer

AU - Litzow, Mark R

AU - Kebriaei, Partow

AU - Hourigan, Christopher S.

AU - Weisdorf, Daniel J.

AU - Saber, Wael

AU - Kharfan-Dabaja, Mohamed A.

PY - 2023

Y1 - 2023

N2 - Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with a poor prognosis and considered incurable with conventional chemotherapy. Small observational studies reported allogeneic hematopoietic cell transplantation (allo-HCT) offers durable remissions in patients with BPDCN. We report an analysis of patients with BPDCN who received an allo-HCT, using data reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). We identified 164 patients with BPDCN from 78 centers who underwent allo-HCT between 2007 and 2018. The 5-year overall survival (OS), disease-free survival (DFS), relapse, and nonrelapse mortality (NRM) rates were 51.2% (95% confidence interval [CI], 42.5-59.8), 44.4% (95% CI, 36.2-52.8), 32.2% (95% CI, 24.7-40.3), and 23.3% (95% CI, 16.9-30.4), respectively. Disease relapse was the most common cause of death. On multivariate analyses, age of ≥60 years was predictive for inferior OS (hazard ratio [HR], 2.16; 95% CI, 1.35-3.46; P = .001), and higher NRM (HR, 2.19; 95% CI, 1.13-4.22; P = .02). Remission status at time of allo-HCT (CR2/primary induction failure/relapse vs CR1) was predictive of inferior OS (HR, 1.87; 95% CI, 1.14-3.06; P = .01) and DFS (HR, 1.75; 95% CI, 1.11-2.76; P = .02). Use of myeloablative conditioning with total body irradiation (MAC-TBI) was predictive of improved DFS and reduced relapse risk. Allo-HCT is effective in providing durable remissions and long-term survival in BPDCN. Younger age and allo-HCT in CR1 predicted for improved survival, whereas MAC-TBI predicted for less relapse and improved DFS. Novel strategies incorporating allo-HCT are needed to further improve outcomes.

AB - Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with a poor prognosis and considered incurable with conventional chemotherapy. Small observational studies reported allogeneic hematopoietic cell transplantation (allo-HCT) offers durable remissions in patients with BPDCN. We report an analysis of patients with BPDCN who received an allo-HCT, using data reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). We identified 164 patients with BPDCN from 78 centers who underwent allo-HCT between 2007 and 2018. The 5-year overall survival (OS), disease-free survival (DFS), relapse, and nonrelapse mortality (NRM) rates were 51.2% (95% confidence interval [CI], 42.5-59.8), 44.4% (95% CI, 36.2-52.8), 32.2% (95% CI, 24.7-40.3), and 23.3% (95% CI, 16.9-30.4), respectively. Disease relapse was the most common cause of death. On multivariate analyses, age of ≥60 years was predictive for inferior OS (hazard ratio [HR], 2.16; 95% CI, 1.35-3.46; P = .001), and higher NRM (HR, 2.19; 95% CI, 1.13-4.22; P = .02). Remission status at time of allo-HCT (CR2/primary induction failure/relapse vs CR1) was predictive of inferior OS (HR, 1.87; 95% CI, 1.14-3.06; P = .01) and DFS (HR, 1.75; 95% CI, 1.11-2.76; P = .02). Use of myeloablative conditioning with total body irradiation (MAC-TBI) was predictive of improved DFS and reduced relapse risk. Allo-HCT is effective in providing durable remissions and long-term survival in BPDCN. Younger age and allo-HCT in CR1 predicted for improved survival, whereas MAC-TBI predicted for less relapse and improved DFS. Novel strategies incorporating allo-HCT are needed to further improve outcomes.

UR - http://www.scopus.com/inward/record.url?scp=85178340125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85178340125&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2023011308

DO - 10.1182/bloodadvances.2023011308

M3 - Article

C2 - 37792849

AN - SCOPUS:85178340125

SN - 2473-9529

VL - 7

SP - 7007

EP - 7016

JO - Blood Advances

JF - Blood Advances

IS - 22

ER -

Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this